

October 2, 2008  
AnGes MG, Inc.

New Medical Use Patent Granted in Europe  
- Covering Severe Diabetic Peripheral Artery Occlusive Diseases -

AnGes MG Inc. announces that a patent for the medicinal use of HGF gene for diabetic ischemic diseases was granted in Europe, and the Patent Gazette (EP1142590B1) was issued on October 1, 2008. This patent is registered as “HGF gene used in the treatment of diabetic ischemic diseases excluding diabetic neuropathy.”

AnGes MG has filed a basic patent application for “a medicament for treating arterial diseases for which HGF is effective, comprising intramuscular administration of an expression vector containing HGF gene” and corresponding patents have been granted in Japan, the USA and Europe, as well as Australia, New Zealand, South Korea and Taiwan.

Ischemic diseases complicated with or caused by diabetes mellitus are known for poorer prognosis because of difficulty in inducing angiogenesis. Under such circumstances, AnGes MG separately evaluated the efficacy of HGF gene for severe diabetic peripheral artery occlusive diseases, and filed its patent application globally.

Regarding the status of the disease, the second edition of Diabetes Atlas Executive Summary, published by the International Diabetes Federation (IDF), states that the total number of diabetes patients in Europe is estimated to be approximately 48 million as of 2003. Although differences are seen among these countries, diabetes patients per country account for an average of 7.8% of the population, higher than the world average of 5.1%.

This invention has been registered in Japan, China and Australia already, and has been registered in Europe now as well. It will be protected until October 2021 in Europe. Patent applications have been filed in the USA, Canada, South Korea, Taiwan and other countries also.

This patent will provide a powerful means of support for AnGes' development project of HGF gene therapy. While also its global development in mind, AnGes MG will continue in its efforts to further establish a strong patent network.